Skip to content
Open access

Precision Oncology in Hematological Malignancies: Pharmacogenomics for Enhanced Therapeutic Efficacy and Diminished Toxicity

Sep 2026 · Journal of Pharmaceutical Research · Vol 25, pp. 141-145 · 0 citations

TL;DR

Pre-emptive genotyping has proven effective in diminishing toxicity rates, as evidenced by juvenile acute lymphoblastic leukemia datasets, achieving a 40–60% reduction in thiopurine-related events and enhancing event-free survival through tailored dosing.

Abstract

Hematological malignancies, including acute and chronic leukemias, lymphomas, and multiple myeloma, continue to present clinicians with diverse responses to traditional chemotherapies and kinase inhibitors due to myelosuppression, off-target effects, and acquired resistance. Pharmacogenomics lets you choose the right dose and regimen by showing how changes in important genes in the germ line affect pharmacokinetics, transporter activity, and target engagement. Critical pharmacogenes encompass ABC transporters (ABCB1, ABCC1) linked to multidrug efflux and relapse risk; cytochrome P450 isoforms (e.g., CYP2C19, CYP3A5) that affect tyrosine kinase inhibitor clearance; and TPMT and NUDT15, which are involved in thiopurine metabolism in acute lymphoblastic leukemia (ALL), where deficient variants lead to severe neutropenia. Pre-emptive genotyping has proven effective in diminishing toxicity rates, as evidenced by juvenile acute lymphoblastic leukemia datasets, achieving a 40–60% reduction in thiopurine-related events and enhancing event-free survival through tailored dosing. High initial costs, low-quality assays, limited access in low-resource areas, and equity disparities among diverse ancestries where NUDT15 variations are common continue to be challenges. Emerging multigene panels, AI-enhanced interpretation, and real-world data from initiatives such as the 100,000 Genomes Project promise improved remission rates and quality of life, indicating potential for further integration. Keywords: Reducing drug toxicity, Variations in TPMT/NUDT15, Precision oncology, Pharmacogenomics, Blood cancers

Read PDF

Similar papers

Review Open access Sep 2026

Search for leukemia-restricted targets: a new paradigm for precision immunotherapy in acute myeloid leukemia.

Acute myeloid leukemia (AML) remains a major therapeutic challenge despite remarkable advances in genomic characterization. Although molecular profiling has transformed disease classification and risk stratification, treatment for most patients continues to rely on cytotoxic chemotherapy regimens developed more than 50...

S. Meshinchi, Franco Locatelli · 0 citations
Review Sep 2026

Menin Inhibitors in Acute Myeloid Leukaemia: Mechanisms, Clinical Pharmacology, and Emerging Therapeutic Strategies.

Acute myeloid leukaemia (AML) remains associated with poor outcomes in relapsed or refractory disease and in molecularly defined high-risk subgroups. AML with KMT2A rearrangements (KMT2Ar) or NPM1 mutations (NPM1m) shares a dependence on the menin-KMT2A interaction, which sustains HOXA/MEIS1-driven transcription requir...

Chen-Chen Ma, Xin Wang, Jing-Yi Wang · 0 citations
Open access Sep 2026

Population-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity

MSK-Tox provides an empirical basis for a new precision safety paradigm for predicting who will be harmed by a therapy on the same principles that guide prediction of therapeutic benefit, and identifies two modes of germline susceptibility to treatment toxicity.

Z. Bakouny, X. Guo, F. Huang et al. · 0 citations
Review Open access Sep 2026

Precision medicine in diffuse large B-cell lymphoma: Integrating molecular biomarkers, targeted therapies, and prognostic tools

It is proposed that the future of DLBCL management lies not merely in the availability of novel agents, but in the rational sequencing and combination of these modalities based on dynamic molecular monitoring and individualized risk assessment—translating molecular insights into actionable clinical pathways.

B. Guo, Hai-Ke Lei, Yao Liu · 0 citations
Review Open access Sep 2026

Cannabinoids in hematologic malignancies: mechanisms and therapeutic potential for overcoming drug resistance

Hematologic malignancies are highly heterogeneous diseases in which the emergence of therapy resistance remains a major obstacle to durable clinical benefit. Cannabinoids, acting through the endocannabinoid system, have drawn increasing interest because of their potential to modulate multiple resistance-associated path...

Si-Xu Li, Xiao-Kun Jian, Yu-Fu Tang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.